Literature DB >> 16200141

The prevalence of hepatitis C virus infection in Texas: implications for future health care.

Kanthi Yalamanchili1, Sherif Saadeh, Rita Lepe, Gary L Davis.   

Abstract

Chronic hepatitis C is often asymptomatic and undiagnosed yet can progress to liver failure or hepatocellular carcinoma. This study determined the prevalence of hepatitis C in Texas and estimated the progression of disease in this cohort. National Health and Nutrition Evaluation Survey III data on the national prevalence of an antibody to the hepatitis C virus were extrapolated to Texas using census data weighted for local characteristics. A Markov model estimated the progression of liver disease. Results showed that 387,395 Texans (1.79%) are infected with the hepatitis C virus. County prevalence varied from 1.25% to 2.63%, with higher rates concentrated along the US-Mexico border. However, most cases of infection were located near major Texas cities. The number of infected persons will decline in the future. However, the proportion of cases progressing to cirrhosis will increase, resulting in more complications such as liver failure and hepatocellular carcinoma. Thus, chronic hepatitis C is common in Texas and will result in an increase in complications of cirrhosis in coming years. The disease will tax health care facilities and transplant units in the state.

Entities:  

Year:  2005        PMID: 16200141      PMCID: PMC1200693          DOI: 10.1080/08998280.2005.11928024

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  21 in total

1.  The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.

Authors:  G L Armstrong; M J Alter; G M McQuillan; H S Margolis
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

2.  Mortality from hepatocellular and biliary cancers: changing epidemiological trends.

Authors:  Satheesh Nair; K Shiv Kumar; Paul J Thuluvath; K S Shivakumar; K Shiva Kumar
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

3.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

Authors:  A Kasahara; N Hayashi; K Mochizuki; M Takayanagi; K Yoshioka; S Kakumu; A Iijima; A Urushihara; K Kiyosawa; M Okuda; K Hino; K Okita
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

4.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

Review 5.  Hepatocellular carcinoma and hepatitis C in the United States.

Authors:  Hashem B El-Serag
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 6.  Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype.

Authors:  L Roffi; A Redaelli; G Colloredo; E Minola; C Donada; A Picciotto; P Riboli; P Del Poggio; G Rinaldi; B Paris; G Fornaciari; M Giusti; R Marin; R Morales; A Sangiovanni; G Belloni; M Pozzi; G Poli; N Mascoli; C Corradi; P Pioltelli; A Scalori; G Mancia
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

7.  Rising incidence of hepatocellular carcinoma in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

8.  Risk factors for the rising rates of primary liver cancer in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  Arch Intern Med       Date:  2000-11-27

9.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

10.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

View more
  11 in total

1.  Aflatoxin and PAH exposure biomarkers in a U.S. population with a high incidence of hepatocellular carcinoma.

Authors:  Natalie M Johnson; Guoqing Qian; Li Xu; Danielle Tietze; Alicia Marroquin-Cardona; Abraham Robinson; Melanie Rodriguez; Linda Kaufman; Kyle Cunningham; James Wittmer; Fernando Guerra; Kirby C Donnelly; Jonathan H Williams; Jia-Sheng Wang; Timothy D Phillips
Journal:  Sci Total Environ       Date:  2010-09-25       Impact factor: 7.963

2.  Hospital-Based Hepatitis C Screening of Baby Boomers in a Majority Hispanic South Texas Cohort: Successes and Barriers to Implementation.

Authors:  Barbara S Taylor; Joshua T Hanson; Poornachand Veerapaneni; Roberto Villarreal; Kristin Fiebelkorn; Barbara J Turner
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

3.  Hepatitis C Virus Infection in the Dallas County Jail: Implications for Screening, Prevention, and Linkage to Care.

Authors:  Caroline M Abe; Merilyne Aguwa; Michelle Zhao; Jacqueline Sullivan; Esmaeil Porsa; Ank E Nijhawan
Journal:  Public Health Rep       Date:  2019-09-17       Impact factor: 2.792

4.  Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012.

Authors:  Donna L White; Aaron P Thrift; Fasiha Kanwal; Jessica Davila; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2016-11-23       Impact factor: 22.682

5.  Opt-out HIV and Hepatitis C Testing at the Dallas County Jail: Uptake, Prevalence, and Demographic Characteristics of Testers.

Authors:  Carolina de la Flor; Esmaeil Porsa; Ank E Nijhawan
Journal:  Public Health Rep       Date:  2017-10-18       Impact factor: 2.792

6.  An Ecological Study of the Association between Air Pollution and Hepatocellular Carcinoma Incidence in Texas.

Authors:  Luca Cicalese; Loren Raun; Ali Shirafkan; Laura Campos; Daria Zorzi; Mauro Montalbano; Colin Rhoads; Valia Gazis; Katherine Ensor; Cristiana Rastellini
Journal:  Liver Cancer       Date:  2017-08-29       Impact factor: 11.740

7.  Incidence and risk factors for hepatocellular carcinoma in Texas Latinos: implications for prevention research.

Authors:  Amelie G Ramirez; Nancy S Weiss; Alan E C Holden; Lucina Suarez; Sharon P Cooper; Edgar Munoz; Susan L Naylor
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

8.  Estimating the prevalence of hepatitis C infection in New York City using surveillance data.

Authors:  S Balter; J H Stark; J Kennedy; K Bornschlegel; K Konty
Journal:  Epidemiol Infect       Date:  2013-05-09       Impact factor: 2.451

9.  Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas.

Authors:  Hyun-Seok Kim; Rosalia Guerrero; Shane W Reader; Maria Daheri; Maya Balakrishnan; Catherine L Troisi; Hashem B El-Serag; Aaron P Thrift
Journal:  Open Forum Infect Dis       Date:  2020-06-02       Impact factor: 3.835

10.  Hazardous air pollutants and primary liver cancer in Texas.

Authors:  Luca Cicalese; Giuseppe Curcuru; Mauro Montalbano; Ali Shirafkan; Jeremias Georgiadis; Cristiana Rastellini
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.